Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.
Ontology highlight
ABSTRACT: Breast cancer (BC) is the most common malignancy affecting women. It is a highly heterogeneous disease broadly defined by the differential expression of cell surface receptors. In the United States, triple negative breast cancer (TNBC) represents 15 to 20% of all BC. When compared with other subtypes of BC, TNBC tends to present in younger women, and has a higher mortality rate of 40% in advanced stages within the first 5 years after diagnosis. TNBC has historically had limited treatment options when compared to other types of BC. The mainstay of treatment for TNBC remains cytotoxic chemotherapy despite the emergence of new biologic and targeted agents. Defining the specific tumor molecular profile including PDL-1 and androgen receptor testing is expanding treatment options in the clinical
SUBMITTER: Bou Zerdan M
PROVIDER: S-EPMC8909187 | biostudies-literature | 2022 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA